# MEDICINE - GASTRO NEET SS



# GASTROESOPHAGEAL REFLUX DISEASE

### Introduction

00:00:25

Seen in 10 % of general population.

GERD → Barrett's esophagus → Adenocarcinoma.

### Types:

- 1. Erosive ERD: 30 %, retractory to PPI (20 to 30 %).
- a. Non erosive ERD (NERD): 70 %, refractory to PPI (40 %).

### Based on the nature of reflux:

 Acidic, weakly acidic, weakly alkaline, gaseous, bile reflux and rereflux.

## Pathophysiology:

- A. Protective factors.
- B. Aggressive factors.

### Protective factors:

A. Antireflux barrier:

### components:

- Intrinsic LES: 3 to 4 cm (a cm above and a cm below)
   and resting pressure is 10 to 30 mmHg.
- Diaphragmatic crura.
- · Intra abdominal location of LES.
- Phrenico esophageal ligament,
- A/c angle of His 1 Between cardia.
   and lower end of esophagus.

# Management Street Stree

### mechanism of GERD:

- 1. t LESR: Diaphragm inhibition (distention of proximal stomach) mediated by stretch receptor of vagal pathway (responsible for 50 to 80 % reflux in GERD).
- a. Swallowing t- LESR 1 5 to 10 % of reflux.

- 4. HH! Esophageal shortening d/t esophagitis 9 decrease in intra abdominal esophagus and in this case there will be increased t-LESR 9 hypotensive LES: 6 to 8 weeks of PPI will improve symptoms.
- 5. Acid pocket: Large cardiac acid pocket.

# B. Oesophageal acid clearance:

- 1. Primary > secondary peristalsis (esophagitis can occur as dysmotility).
- a. Gravity will assist (first and second constitute volume clearance).
- 3. Salivary secretion and oesophageal secretion protect and increase GERD in xerostomia and smoking (secretion clearance).

### C. Tissue resistance:

- 1. Pre epithelial: mucin production.
- 2. Epithelial: EGF, TGF increase cell turnover.
- 3. Post epithelial blood supply.
- 4. Dilated intercellular spaces is seen in early GERD.

# Aggressive factors:

- 1. Gastric acid secretion.
- a. Duodenogastric reflux.
- 3. Delayed gastric emptying.

### Clinical features 1

# Oesophageal 1

- Heart burn (90 % specific and 40 % sensitive) : Pyrosis and m/c symptom and TRPM mediated.
- · Regurgitation : Stooping forward.
- . Dysphagia 1 Stricture (GERD improves) and Schatzki ring.
- · Water brash.
- · Odynophagia.
- · Hiccups.

Aring	B ring (Schetzki's ring)
Upper end of LES covered by squamous epithelium	Squamocolumner junction and upper part by squamous and lower by columner
Muscular ring	No muscle layer
Lose common	More common
No GERD esecutation	GERD essociation
Treatment : Dilation POEM Botulinum	Treatment: Distortion Endoscopie resection

### extra oesophageal:

- Chest pain.
- Pulmonary: Asthma, c/c bronchitis, IPF and bronchiectasis.
- ENT : Globus, hoarseness, leucoplakia, post laryngitis.
- · Sleep: OSAS.

Decrease LES pressure	Increase LES pressure
· VIP · CCK	Gastrin     Motilin
• Secretin	Substance P
<ul> <li>Sometostatin</li> <li>Alpha antagonist</li> </ul>	
Beta agonist	
Ach antagonist Serotonin, Dopamine	
Morphine, CCB	- T.V
• Barbiturate, BCZ • Fat , peppermint	ACCOUNT NAME OF THE OWNER, THE OW

# Diagnosis

00:27:49

Endoscopy: Look for esophagitis, Barrett's esophagus, HH Landmarks:

- · Location of hiatus.
- Anatomical & junction.
- Squamocolumnar junction.

Distance between hiatus and anatomical GE > 2 cm : Hiatus hernia.

ESEM (Endoscopically Significant Barrett's Mucosa): Distance between SCJ and anatomical 62 > 1 cm.
Biopsy should be taken (Prague guidelines).
Histology: Gastric or intestinal metaplasia.
According to UK quidelines: ESEM with either one.

If biopsy is inconclusive: Repeat biopsy after 8 to 12 months. If no esophagitis then NERD (Bx: Barrett's + r/o EOE).

Table 2: Classification of Visual or Macroscopic Reophogists in Children and Adults — Helsel-Dont and LA Classification

Grade 9 Grade 1	Normal mucosa Mucosal edema, hyperemia, and frieblity
Grade 2	Superficial erostons involving less than 10% of the distal 5 cm of the exceptagest mucosal surface
Grade \$	Superficial erosions and ulcerations involving 10-50% of the distal esophagus
Grade 4	Deep peptic ulceration anywhere in the esophagus or confluent erosion of more then 50% of the distal esophagus

Cheeffication
One (or more) mucosal breek no longer than 5 mm that does not extend
between the tops of two mucosal folds



One (or more) mucosal break more than 5 mm that does not extend between the tops of two mucosal folds




One (or more) mucosal break that is continuous between the tops of two mucosal folds but which involves less than 75% of the circumference



One (or more) mucosal bri



# Hill grading:





axially

with respiration

# Pathological GERD:

Grade C/D esophagitis	Barrett's oesophagus
Peptic stricture	AET > 6%

# Indication for GERD testing:

Incomplete or lack of response to PPI	
Prior and following anti-reflux Sx	
Atypical symptoms like cough, belching, suspected rumination	

# Types of testing include:

- PH metry (gold standard for diagnosis of GERD).
- PH metry + impedance testing: Can detect weakly acidic + weakly alkaline + gaseous and rereflux.

# Demister score (pH metry + impedance):

Total AET	Recumbent AET	Upright AET
Number of reflex	Longest reflex	Reflux with PH < 4 0r > 5 min

AET < 4 % is normal and > 6 % is abnormal and 4 to 6 % is grey area.

> 80 reflux/24 hr is abnormal and < 40 reflux/24 hr is normal. Probe is placed 5 to 6 cm from squamocolumnar junction. Testing with or without PPI.

# Demister score (pH metry + impedence):

With PPI	Without PPI
Prior PH teating +ye	Confirm reflux is the cause of
Barrett's oesophagus	symptom
Grade C/D esophagitis	Testing prior to anti reflux sx
Peptic stricture	Non erosive disease
	Grade A/B esophagitis
	No Barrett's
	Atypical presentation
	Absent or incomplete response to PPI
	Recurrent or perelatent symptoms
	following enti-reflux ex
	Better symptom reflux association

# Lifestyle modification :

Weight loss	Head elevation	Avoid Smoking and R-OH
Avoid late snack	Lying down following meal	Tight clothes

OTC: Gaviscon is better than antacid.

### Prokinetics:

- · Increase LES pressure and gastric emptying.
- Not effective alone (80 % due to t LESR and prokinetic do not alter it.

Cisapride → arrythmia	Metoclopramide → EPS
Domperidone → QT prolongation	Bethanechol→ flushing +blurring+ increase HZ

### t LESR inhibitors:

- Backofen (GABA agonist).
- · Placarbil, lesogaberan, arbaclofen: Better tolerability.
- No significant benefit.

# HaR antagonist:

· Less effective than PPI.

### PPI:

- Response is better for erosive ERD than NERD.
- · Double dose more effective when given in divided doses.
- Ex: 80 mg 00 pantoprazole < 40 mg 60 pantoprazole,</li>
   80 mg > 40 mg.
- Decrease heartburn and esophagitis but reflux will continue.
- · Give for 8 week and If no response for 12 week.
- · Esameprazole: superior than others in Los angels C 9 D.

### maintenance of PPI if 1

Low LES pressure	Esophagitis
Young patient require maximum	m therapy

Fundic polyp	Gastric carcinoid	Ca colon
Increase pneumonia	Enteric infection and SBP	Osteoporosis
SIBO	Hypomagnesemia	Decrease Iron absorption
Interstitial nephritis	Inhibit clopidogrel al	osorption

### Endoscopic procedures:

	Anti-Reflux surgery by endo	scopy
RFA	TOF (Transoral fundoplication)	MUCOSAL RESECTION
• Stretta	<ul> <li>GERD</li> <li>MUSE (Medigus ultrasound surgical endostapler)</li> <li>ESOPHY</li> </ul>	Anti-Reflux     mucosectomy     Anti-Reflux     mucosal ablation

### RFA:

- Upto 14 application of radiofrequency energel<sup>n</sup>/<sub>1</sub>2(4) testile
   balloon catheter system to LES muscle q gastric cardia.
- moa: Hypertrophy of muscularis propria and reduced
   Les relaxation + fibrosis of Gejn.
- · Confounding result b/w stretta vs PPI.
- · No RCT comparing Stretta vs Anti Reflux Sx.
- A/e: Chest pain, fever, oesophageal ulcer, rarely gastroparesis (vagal nerve injury).

### TOF:

- a70° fundoplication under GA.
- · Better response in:

Hills grade I-II	Small hiatus hernia
Typical GERD	Normal HRM
symptoms	oesophagus

# ARM (Anti Reflux mucosectomy) !

- · mucosa resected and heal with scar formation.
- Resect a cm gastric and I cm oesophageal mucosa in crescentic fashion.

# Surgery!

· Preprocedure : Do pH metry + HRM (r/o CREST and

Achalasia).

- For refractory GERD (20 to 30 % of erosive ERD and 40 % NERD have poor response to PPI.
- If achalasia, partial fundoplication + myotomy is required other wise cause dysphagia, in others: 360
   Nissen fundoplication.
- · Ne: Dysphagia, bloating and flatulence.

### Indication:

- PPI controlled -> desiring alternative treatment
- Vol regurgitation and aspiration
- Recurrent peptic stricture in young
- Barrett's rarely regress

# Failed surgeries:

- Too tight fundoplication
- Breakdown fundoplication
- Malposition fundoplication
- · Herniation of fundoplication
- Paraesophageal hernia

HH surgery + Nichol Collin lengthening procedure. Fundoplication: No difference in recurrence between laparotomy and laparoscopy.

# Types:

- I. Complete:
  - Nissen 360°.
- a Partial:
  - Posterior :
    - Toupet a70°.
    - Lind 300°.
  - Anterior:
    - · Belsey mark IV.
    - · Dor hemifundoplication.

as % require PPI on follow up and 15 to 30 % require reintervention.



MSA (magnetic Sphincter Augmentation)/LINX system):

- Newer surgical technique where titanium beads with magnetic core placed around lower oesophagus and it separated during swallowing and belching.
- A/e: Dysphagia, perforation.

# **EOSINOPHILIC ESOPHAGITIS**

# Food hypersensitivities

00:00:28

# **BOX 10.2** Gastrointestinal Food Hypersensitivities

### MMUNOGLOBULIN E-MEDIATED FOOD HYPERSENSITIVITIES

GI allergy

Infantile colic (minor subset)

Pollen-food allergy (oral allergy syndrome)

MIXED IMMUNOGLOBULIN E- AND NON-

MMUNOGLOBULIN E-MEDIATED HYPERSENSITIVITIES

Ecstrophilic esophagitis

Eosinophilic gastritis

Ecsinophilic gastroenteritis

Allergic eosinophilic proctocolitis

### NON-IMMUNOGLOBULIN E-MEDIATED FOOD altonersensitivities

Dietary protein-induced enteropathy

Cellac disease

Dermatitis herpetiformis

Food protein-induced enterocolitis syndrome

### **MECHANISM UNKNOWN**

Cow's milk-induced occult GI blood loss and Iron deficiency anemia of infancy

GERD

Infantile colic (subset)

**IBO** 

### Infantile colic:

- 5 to 10 %: IqE mediated.
- 90 to 95 %: mechanism is unknown.

# Background!

First diagnostic guidelines in 2007 AGREE conference was held in Chicago

2011

2007

2017

Updated in 2011

AGREE: Awaking Group On PPI Responsive Esophageal Eosinophilla

## Gastroenterology

eosinophilic esophagitis (eoe): a007 definition:



Dysphagia, food impaction, chest pain, abdominal pain, vomiting, failure to thrive.

### Other causes:

Achalasia, collagen vascular disease, coeliac disease, crohn's disease, drugs, other EGIT disease, GERD, GVHD, vasculitis, hypereosinophilic syndrome, pemphigus vegetans.

### modification in aoII:

Subset of patients who responded to PPI were excluded from the definition.

New phenotype - PPI REE ( PPI responsive Eosinophilia) needed to be addressed

The updated guidelines still required three criteria to be met, but with some modifications:

- 1) clinical symptoms of esophageal dysfunction
- 2) a maximum esophageal eosinophil count of at least 15 eos/hpf, with few exceptions
- 3) exclusion of other possible causes of esophageal eosinophilia, including PPI-REE.

In 2017, AGREE consensus:

PPI responsive patients were again included in the definition. PPI is used as treatment option.

Another gene- Chromosome 5-TSLP

Ectaxin a: Associated with ecsinophilic gastroenteritis.

Clinical features:

**Typical Presentation** 

Atopic male (Male: Female, 3:1)

Presents in childhood or the 3rd or 4th decade

Dysphagia (solid food), chest pain, food impaction (requiring endoscopic removal in 33 to 54 %) and upper abdominal pain.

a/3rd of patients will have allergic manifestations/atopy.

### SYMPTOMS ACCORDING TO AGE



Infants and toddlers-Failure to thrive and feeding difficulties



School aged children-Vomiting or pain



Adults- Dysphagia, food impaction, chest pain and upper abdominal pain.

Table 2. Clinical presentation of adult EoE patients enrolled in a European multicenter trial [14]

Patients	76
Males, %	83
Mean age (range), years	39.7 (18-70)
Mean BMI (range)	24.8 (19.0-36.7)
Symptoms, %	
Dysphagia	100.0
Food impaction	65.8
Odynophagia	35.5
Retrosternal pain	38.3
Heartburn	32.9
Regurgitation	35.5
Abdominal pain	18.4
Diarrhea	7.8
Weight failly	2.6
Allergic comorbidities, %	64.5
Allergic rhinitis	50.0
Allergic conjunctivitis	19.7
Allergic asthma	19.8
Atopic eczema	
Food allergies	9.2
	21.1
Duration of dysphagia >1 year, %	50

Table 1. Similarities and differences in the chaical appearance of pediatric and adult EoE (adapted from [5])

	Adults	Children
Symptoms	dysphagia (solid food), food impaction, retrosternal pain	abdominal pain, chest pain, heartburn coughing, decreased appetite, food refusal, anorexia, dysphagia, nausea, regurgitation, sleeping difficulties
Demographics	male Caucasians predominant	
Physical exam	normal	sometimes failure to thrive
Allergic predisposition	airborne allergens predominant	food allergens predominant
Concomitant allergic diseases	asthma, eczema, allergie rhinitis	
Lab values	peripheral eccinophilia 5-50%, total serum IgE =70%	

# Endoscopic features:

None of them are pathognomonic.

Fixed esophageal rings or trachealization/corrugated rings Transient esophageal rings (felinization or feline folds)

Whitish exudates

Longitudinal furrows

Edema

Diffuse esophageal narrowing

Narrow calibre esophagus

Esophageal lacerations induced by the endoscope

Fig. 1. Endoscopic manifestations in addit EoE patients enrolled in a European multicenter trial white exudate (a), longitudinal furrows (b), diffuse oderna (c), fixed rings (d), severe stricture (e), and rings, furrows and adden (f) [1,4]

## Endoscopic biopsy:

2 to 4 biopsies from the proximal and distal esophagus should be obtained.

In children - Gastric and duodenal biopsies also

# Histopathology:

### Eosinophils > 15/hpf

- · Eosinophil micro abscess formation
- · Superficial layering of eosinophils

Extracellular eosinophil granules

Dilated intercellular spaces


Elongated papillae with inflammation and fibrosis and lamina propria

Basal cell hyperplasia

Eosinophilic gastroenteritis: > 30 eosinophils/hpf. Rule eoe.

Normal esophagus:

Eosinophilic esophagitis:
Esophageal epithelium from
a patient with EoE shows a
markedly thickened basal
layer (bar)
numerous intraepithelial
eosinophils (arrows)
dilated intercellular spaces
(white arrow)



and thickened fibers in the lamina propria (asterisk). Eosinophilic microabscesses at the surface (arrows). Dilated intercellular spaces are also seen (white arrow).

Other diagnostic modalities:

Esophageal pH monitoring and impedence to evaluate GERD

EUS- may show greater mucosal and muscular thickness

Radiography is no routinely indicated;
Maybe used in the likelihood of strictures

# Lab investigations:


Peripheral eosinophilia and elevated serum IgE levels are usually found in 50 and 75% of patients, respectively.

Food-specific IgE or skin prick test results may be positive in over 80% of adult EoE patients

However, elimination of foods that gave positive results failed to achieve disease remission.

None of the currently available techniques has proven useful or reliable for the management of EoE in clinical practice

15



# theintroduction should begin with least likely food trigger !

### ADULTS

- Wheat 60%
- Milk 50 %
- Soy 10%
- Nuts 10%
- Eggs 5%

### **PAEDIATRICS**

- Milk- 35%
- Egg- 13%
- Wheat- 12%
- Soy- 9%

## Drug therapy:



1

Systemic or topical steroids can be used in treatment of EoE.

2

Systemic steroids are used in acute exacerbations while topical for maintenance.

### TABLE III. Recommended doses of corticosteroids for EoE

Topical swallowed corticosteroids

Initial doses (see references for preparation and administration information)

Fluticasone (puffed and swallowed through a metered-dose inhaler)

Adults: 440-880 µg twice daily

Children: 88-440 µg twice to 4 times daily (to a maximal adult dose)

Budesonide (as a viscous suspension)
Children (<10 y): I mg daily

Older children and adults: 2 mg daily

Systemic corticosteroids

For severe cases (eg. small-caliber esophagus, weight loss, and hospitalization)

PrednishW: 491949/84

In trial:

IL-5 humanized antibodies-Mepolizumab and Rezlizumab.

Chemoattractant receptor of Th2 cells (CRTH2) antagonists

